Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass
暂无分享,去创建一个
Klaus Engelke | Thomas Fuerst | Cesar Libanati | Jacques P. Brown | H. Genant | A. Grauer | T. Fuerst | K. Engelke | S. Goemaere | C. Libanati | C. Recknor | C. Mautalen | Stefan Goemaere | M. Bolognese | Andreas Grauer | Carlos Mautalen | Michael A Bolognese | Harry K Genant | Jacques P Brown | Chris Recknor | Yu‐Ching Yang | Yu-Ching Yang | Yu‐ching Yang
[1] Y. Rhee,et al. Differences in femoral neck geometry associated with age and ethnicity , 2011, Osteoporosis International.
[2] F. Melsen,et al. Marked changes in iliac crest bone structure in postmenopausal osteoporotic patients without any signs of disturbed bone remodeling or balance. , 1994, Bone.
[3] Terry M Therneau,et al. Proximal femoral density distribution and structure in relation to age and hip fracture risk in women , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] H. Genant,et al. Advanced CT based In Vivo Methods for the Assessment of Bone Density, Structure, and Strength , 2013, Current Osteoporosis Reports.
[5] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[6] V. Bousson,et al. QCT of the proximal femur—which parameters should be measured to discriminate hip fracture? , 2016, Osteoporosis International.
[7] P. Delmas,et al. Severity of Vertebral Fractures Is Associated With Alterations of Cortical Architecture in Postmenopausal Women , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] H. Ke,et al. Tissue‐Level Mechanisms Responsible for the Increase in Bone Formation and Bone Volume by Sclerostin Antibody , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[9] H. Genant,et al. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis. , 2010, Bone.
[10] Maria Luisa Brandi,et al. Microarchitecture, the key to bone quality. , 2009, Rheumatology.
[11] Cesar Libanati,et al. Romosozumab in postmenopausal women with low bone mineral density , 2014, The New England journal of medicine.
[12] E. Posvar,et al. Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] D. Lacey,et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] Qing Chen,et al. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] A. Kivitz,et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double‐blind, placebo‐controlled study , 2014, Journal of clinical pharmacology.
[16] H. Macdonald,et al. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis , 2010, Osteoporosis International.
[17] R. Rizzoli,et al. Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis , 2011, Osteoporosis International.
[18] Gabriele Armbrecht,et al. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. , 2008, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[19] Sharmila Majumdar,et al. A Longitudinal HR-pQCT Study of Alendronate Treatment in Postmenopausal Women With Low Bone Density: Relations Among Density, Cortical and Trabecular Microarchitecture, Biomechanics, and Bone Turnover , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] G. Dalsky,et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. , 2005, Archives of internal medicine.
[21] P. Kostenuik,et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[22] Willi A Kalender,et al. Reanalysis precision of 3D quantitative computed tomography (QCT) of the spine. , 2009, Bone.
[23] R. Rizzoli,et al. Bone strength and its determinants , 2003, Osteoporosis International.
[24] R. Recker,et al. Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. , 2007, Bone.